• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

With biosim­i­lars gain­ing mo­men­tum, Am­gen and Al­ler­gan cite suc­cess of Her­cept­in's copy­cat

9 years ago
R&D

The Scan­gos lega­cy: A block­buster MS record with lin­ger­ing doubts about the pipeline

9 years ago
R&D

Side­lined at the FDA, As­traZeneca watch­es as new team seizes ri­val drug in $1.5B Re­lyp­sa buy­out

9 years ago
R&D

New CEO Szela cuts Aege­ri­on staff again, pulls Jux­tapid out of the EU

9 years ago
R&D

BioReg­num: An­oth­er great rea­son emerges for As­traZeneca to tar­get new biotech deals

9 years ago
Bioregnum
Opinion

Mer­ck is scout­ing sites for a new re­search hub in the Bay Area, plans new hires

9 years ago
R&D

As­traZeneca culls its neu­ro­science team, ex­its Kendall Square of­fice

9 years ago
R&D

By the num­bers: 2-year tal­ly of Cel­gene's biotech part­ner­ship deals tops $3B in cash

9 years ago
R&D

AveX­is wins the in­side track at the FDA with gene ther­a­py ‘break­through’

9 years ago
R&D

Syn­thorx lines up some big syn­thet­ic bi­ol­o­gy R&D goals af­ter grab­bing a $10M round

9 years ago
R&D

Be­lea­guered Zaf­gen crushed af­ter FDA de­mands force it to dump lead drug

9 years ago
R&D

Valeant wins first round in $445M gam­ble on bro­dalum­ab ap­proval

9 years ago
R&D

Mer­ck KGaA blue­prints a $115M 'col­lab­o­ra­tion cam­pus' for Mass­a­chu­setts

9 years ago
R&D

Mer­ck-backed Quar­tet places biotech vet Ger­hard Koenig at the helm

9 years ago
R&D

Cel­gene signs Jounce as its new biotech star in $2.6B ‘im­muno-on­col­o­gy 2.0’ pact

9 years ago
R&D

Cel­gene EVP Bag­ger gets a plum as­sign­ment on Trump team

9 years ago
R&D

Biotech vet Gould lands $55M start­up round for a new Third Rock plat­form biotech

9 years ago
R&D

No­var­tis’ cam­paign to sweep biosim­i­lar ap­provals hits a set­back

9 years ago
R&D

Brain­storm’s ral­ly fiz­zles af­ter in­vestors turn sour on ques­tion­able ALS da­ta

9 years ago
R&D

Play­ing de­fense, Roche los­es megafran­chise gam­bit as Gazy­va flunks head-to-head with Rit­ux­an

9 years ago
R&D

With cash run­ning low, lit­tle Evoke los­es a cru­cial PhI­II gam­ble

9 years ago
R&D

Which big bio­phar­ma com­pa­nies put R&D as their top pri­or­i­ty?

9 years ago
R&D

No min­is­ter: UK biotech com­mu­ni­ty los­es its ded­i­cat­ed gov­ern­ment min­is­ter

9 years ago
R&D

Zio­pharm craters on re­port of pa­tient death in gene ther­a­py study

9 years ago
R&D
First page Previous page 1173117411751176117711781179 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times